Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer.

Hui PengC Alston JamesDarren R Cullinan Graham D HoggJacqueline L MuddChong ZuoRony Takchi Katharine E Caldwell Jingxia LiuDavid G DeNardoRyan C FieldsWilliam E GillandersS Peter GoedegebuureWilliam G Hawkins

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Our study reveals that neoadjuvant chemotherapy with FOLFIRINOX enhances effector T cells and downregulates suppressor cells. These data indicate that FOLFIRINOX neoadjuvant therapy may improve immune therapy and clinical outcome in patients with PDAC.

Keyphrases

locally advanced
neoadjuvant chemotherapy
rectal cancer
induced apoptosis
squamous cell carcinoma
lymph node
radiation therapy
dendritic cells
sentinel lymph node
regulatory t cells
endoplasmic reticulum stress
electronic health record
bone marrow
immune response
early stage
big data
type iii